Project Grant R21NS150178
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $249K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke awarded The Ohio State University $234,006 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop a novel pipeline for antigen discovery in Guillain-Barré Syndrome using single-cell T-cell receptor data and artificial intelligence-based ligand prediction. The project addresses the gap between GBS pathogenesis—driven by molecular mimicry in which...
- The National Institute of Neurological Disorders and Stroke awarded the University of Texas Health Science Center at Houston $234,000 on September 3, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to elucidate novel immunomodulatory mechanisms of neonatal Fc receptor blockade by efgartigimod in a T cell-mediated demyelinating neuropathy model. The award funds research examining how efgartigimod, a recombinant human IgG1 Fc...
- The National Institute of Neurological Disorders and Stroke awarded the University of South Carolina $237,254 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to conduct a national retrospective cohort study of health care quality and outcomes among Medicare patients with Guillain-Barre syndrome. The recipient will perform a retrospective analysis of traditional Medicare claims and Medicare Advantage encounter data...
- The National Institute of Neurological Disorders and Stroke awarded Loyola University of Chicago Health Sciences Campus $342,420 on August 21, 2026, under CFDA 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders) to conduct preclinical development of FGTI-2734, a prenyltransferase inhibitor, as a potential therapeutic for acute inflammatory demyelinating polyneuropathy (AIDP), the Guillain-Barré syndrome variant. The R61/R33 IGNITE application funds investigation...
- The National Institute of Allergy and Infectious Diseases awarded $231,000 to the Regents of the University of Minnesota on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research investigates the paradoxical role of antibiotic therapy in increasing the risk of Guillain-Barré syndrome (GBS), an acute autoimmune neuropathy. The work examines how antibiotics upregulate lipooligosaccharide (LOS) production in Campylobacter jejuni, the leading...
- The National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services National Institutes of Health, awarded the University of Virginia $236,896 on February 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to explore the link between enteric glial cells and multiple sclerosis etiology. The research investigates the hypothesis that enteric glial cells in the gastrointestinal tract may...
- The National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services National Institutes of Health, awarded $475,659 to the University of Texas at Dallas on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to study blood-brain barrier dysfunction during bacterial meningitis. The research employs state-of-the-art human stem-cell modeling techniques to assess how brain...
- The National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services, awarded $739,268 to Yale University on March 20, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate skin biopsy as a biomarker for chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a rare autoimmune disorder affecting the peripheral nervous system with heterogeneous clinical presentation...
- The National Institute of Neurological Disorders and Stroke awarded the University of Massachusetts Medical School $551,557 on August 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate nucleic acid sensing pathways in demyelinating disease. The funded research dissects the role of endosomal toll-like receptors (eTLRs) in neuroinflammation and demyelination, specifically examining how aberrant eTLR signaling in...
- The National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services National Institutes of Health, awarded the University of New Haven, Incorporated $208,800 on March 20, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to characterize the role of the long noncoding RNA LINC01896 in glioblastoma multiforme. The research will investigate how LINC01896, significantly upregulated in...